New strategy aims to stop aggressive lymphoma from coming back
NCT ID NCT05256641
Summary
This study is testing whether adding a maintenance drug called acalabrutinib after cellular therapies (like stem cell transplants or CAR-T cell therapy) can help prevent aggressive lymphoma from returning in patients at very high risk of relapse. Researchers want to see if this extra treatment is safe and effective at keeping the cancer away longer. The study involves 24 adults who have recently undergone one of these cellular therapies for specific types of aggressive B-cell lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Oklahoma
NOT_YET_RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.